Sugi Predict

Sugi Predict / Compounds / SCHEMBL4851027

SCHEMBL4851027

SCHEMBL4851027

COc1cc(N)c(C(=O)c2ccccc2)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.54
▸ LMNA P02545 5/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ HPGD P15428 3/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ MAPK1 P28482 3/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ GAA P10253 1/20 0.49
▸ HTT P42858 3/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ RAB9A P51151 1/20 0.47
▸ MAPK14 Q16539 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ CYP2D6 P10635 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353001 0.88 MAPT (0.56) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL4707952 0.87 MAPT (0.59) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL5492977 0.83 MAPT (0.77) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL6113449 0.83 MAPT (0.58) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL19554326 0.82 KDM4E (0.51) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL5537008 0.82 MAPT (0.60) MAPTLMNAKDM4EHSD17B10MAPK1
SCHEMBL3821668 0.81 RECQL (0.52) MAPTLMNAKDM4EHPGDRECQL
SCHEMBL10959090 0.80 MAPT (0.58) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL9357665 0.79 MAPT (0.54) MAPTLMNAKDM4EHPGDHSD17B10
SCHEMBL5489041 0.78 LMNA (0.52) MAPTLMNAKDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 — — US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 — — US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 — — US disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES MAPT 472/4885LMNA 3150/4885KDM4E 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.